GcMAF for metastatic breast cancer: a pilot study
Part of Cancer, Skin clinical trials.
This study tests a new treatment called GcMAF (Soloways) for women with metastatic breast cancer. It is a placebo-controlled pilot study, meaning some participants will get the study drug and some will get an inactive pill. The goal is to see if GcMAF can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- You have breast cancer that has spread to other parts of the body (metastatic).
- You have already tried at least one standard treatment for your cancer, like chemotherapy or hormone therapy.
- Your blood tests show that your bone marrow, liver, and kidneys are working well enough.
- You have not had treatment with GcMAF before.
- Your nagalase levels are higher than normal, which suggests active tumor activity.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
This trial tests a new drug called GNC-077 for people with advanced breast cancer or other solid tumors that have spread. It aims to see if the drug is safe and effective.
This trial tests a drug called mitazalimab injected directly into the tumor for patients with early-stage or recurrent breast cancer who are scheduled for surgery. The goal is to see if this approach can help the immune system fight the cancer before surgery.
This Phase 2 study tests treatments guided by blood testing (“liquid biopsy”) in people with hormone receptor–positive, HER2-negative metastatic breast cancer that has progressed after standard CDK4/6 medicine plus hormone therapy. It aims to find a better way to control cancer after the first treatment stops working.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This Phase 1 trial tests a new drug called GB18 to help cancer patients who have experienced significant weight loss and muscle wasting—a condition called cancer cachexia. The drug works by targeting a specific protein involved in weight loss, and researchers want to learn if it can help patients regain weight and strength while also being safe.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.